MPHARM ALLIANCE LTD

Company Registration Number:
13209249 (England and Wales)

Unaudited abridged accounts for the year ended 28 February 2023

Period of accounts

Start date: 01 March 2022

End date: 28 February 2023

MPHARM ALLIANCE LTD

Contents of the Financial Statements

for the Period Ended 28 February 2023

Company Information - 3
Balance sheet - 4
Additional notes - 6
Balance sheet notes - 9

MPHARM ALLIANCE LTD

Company Information

for the Period Ended 28 February 2023




Director: Mohammad Afzaal Afzal
Registered office: 2a Mayfield Avenue
King Cross
Halifax
GBR
HX1 3XE
Company Registration Number: 13209249 (England and Wales)

MPHARM ALLIANCE LTD

Balance sheet

As at 28 February 2023


Notes

2023
£

2022
£
Fixed assets
Tangible assets: 4 187,500 175,406
Total fixed assets: 187,500 175,406
Current assets
Debtors: 100
Cash at bank and in hand: 10,636 46,136
Total current assets: 10,636 46,236
Creditors: amounts falling due within one year: ( 41,797 ) ( 31,328 )
Net current assets (liabilities): ( 31,161 ) 14,908
Total assets less current liabilities: 156,339 190,314
Creditors: amounts falling due after more than one year: ( 104,357 ) ( 172,381 )
Provision for liabilities: ( 2,654 ) ( 499 )
Total net assets (liabilities): 49,328 17,434

The notes form part of these financial statements

MPHARM ALLIANCE LTD

Balance sheet continued

As at 28 February 2023


Notes

2023
£

2022
£
Capital and reserves
Called up share capital: 100 100
Profit and loss account: 49,228 17,334
Shareholders funds: 49,328 17,434

For the year ending 28 February 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 18 November 2023
And Signed On Behalf Of The Board By:

Name: Mohammad Afzaal Afzal
Status: Director

The notes form part of these financial statements

MPHARM ALLIANCE LTD

Notes to the Financial Statements

for the Period Ended 28 February 2023

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

MPHARM ALLIANCE LTD

Notes to the Financial Statements

for the Period Ended 28 February 2023

  • 2. Employees


    2023

    2022
    Average number of employees during the period 0 0

MPHARM ALLIANCE LTD

Notes to the Financial Statements

for the Period Ended 28 February 2023

  • 3. Off balance sheet disclosure

    No

MPHARM ALLIANCE LTD

Notes to the Financial Statements

for the Period Ended 28 February 2023

4. Tangible Assets

Total
Cost £
At 01 March 2022 176,281
Additions 1,000
Disposals -
Revaluations 12,219
Transfers -
At 28 February 2023 189,500
Depreciation
At 01 March 2022 875
Charge for year 1,125
On disposals -
Other adjustments -
At 28 February 2023 2,000
Net book value
At 28 February 2023 187,500
At 28 February 2022 175,406